A Phase 2 interventional study of Triamcort and Platelet-rich-plasma in Osteoarthritis, Knee, sponsored by Balgrist University Hospital. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-07.
Sponsored by Balgrist University Hospital · Phase 2, Interventional, and Treatment
This study investigates clinical outcome and imaging outcome parameters after intraarticular injection of steroids, platelet-rich-plasma (prp), hyaluronic acid or placebo in patients with early osteoarthritis of the knee joint.
Osteoarthritis of the knee joint is a very common disease in middle aged and elderly patients. This study evaluates the efficiency of different commonly used substances for intraarticular, non-operative treatment in early stages of this disease.
120 patients receive an fluoroscopic guided injection in the knee joint: 30 patients get injection with steroids 30 patients get injection with prp 30 patients get injection with hyaluronic acid 30 patients get injection with placebo (iopamiro contrast media)
Primary outcome: - clinical outcome (pain using numeric rating scale)
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's enrollment of 120 is above the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →Balgrist University Hospital is the lead sponsor of 80 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion criteria:
-age under 18, gonarthritis, Kellgren 4, anticoagulation therapy, known inflammatory disease or infection, cardiovascular disease NYHA IV, immunosuppression, contraindication for MRI, pregnancy, no informed consent, NSAR 3 days before injection, etc.
30 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)
Drug: Triamcort
30 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)
Drug: Platelet-rich-plasma
30 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)
Drug: Suplasyn1
30 patients receive intraarticular injection with contrast media only
Drug: Placebo
Fluoroscopic guided injection in the knee joint
Pain assessment
numeric rating scale (NRS) and WOMAC
Time frame: up to 24 months after injection
Magnetic Resonance imaging
cartilage volume (ml)
Time frame: up to 12 months after injection
Magnetic Resonance imaging
T2-values in cartilage (mean Signal +/- Standard Deviation) in subregions
Time frame: up to 12 months after injection
WOMAC score (stiffness, difficulty)
Clinical outcome
Time frame: up to 24 months after injection
Tegner Activity Scale
Clinical outcome
Time frame: up to 24 months after injection
Knee mobility and thigh circumference
Clinical assessment, comparison to baseline
Time frame: 3 month after injection
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balgrist University Hospital